OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.
By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.
DES(1-3) IGF-1. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Low reported | 50 mcg | 1× daily | 0.125 mL | 12.5 u | 20 doses | |
| Standard | 100 mcg | 1× daily | 0.25 mL | 25 u | 10 doses | |
| Upper reported | 150 mcg | 1× daily | 0.375 mL | 37.5 u | 6 doses |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial | |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 50 mcg | daily | 0.125 mL | 12.5 u | 14 | 0.7 mg |
| Weeks 3–4 | 100 mcg | daily | 0.25 mL | 25 u | 14 | 1.4 mg |
| Week 5 onward per 4 weeks from here on |
150 mcg | daily | 0.375 mL | 37.5 u | 28 | 4.2 mg |
A truncated IGF-1 variant with roughly tenfold higher potency at the receptor but a very short half-life, hence its reputation as a localised agent. Preclinical only.
Buy IGF-1 DESthis peptideOpens optimal-pep.com in a new tab
Browse the full catalogue, or jump to a neighbouring compound.
An IGF-1 analogue engineered to resist binding-protein sequestration, giving far longer activity than native IGF-1. Carries genuin…
A splice variant of IGF-1 expressed in muscle after mechanical loading, implicated in satellite cell activation. Extremely short-l…
Every compound compared in one table: dose range, how often, half-life and evidence tier.